It is well established that early recanalization is associated with improved outcomes: in the recent Hermes analysis \[[@B1]\], rates of functional independence after endovascular thrombectomy (EVT) were 64% with reperfusion at 3 hours vs. 46% with reperfusion at 8 hours. In this analysis, thrombectomy up to 7.3 hours after symptom onset was associated with improved outcomes. Inclusion of patients with CT and CT angiography (CTA) within 6 hours formed the basis for three of the recent trials \[[@B2][@B3][@B4]\] and this has led to construction of national and international guidelines incorporating these criteria \[[@B5][@B6][@B7]\].

Despite campaigns to heighten public awareness, a significant proportion of patients present to or are referred to comprehensive stroke centers offering interventional treatment beyond the six hour therapeutic window \[[@B8]\], with only 11-12% of UK stroke admissions in 2014 being eligible for IV thrombolysis \[[@B9]\]. It has been demonstrated that the size of the core infarct at presentation is highly variable and is independent of time from stroke onset \[[@B10]\]. The weight of evidence suggests that core infarct growth is heavily dependent on the collateral flow to the ischemic penumbra \[[@B11][@B12]\]. Factors that govern collateral failure are not well understood but it has been shown that in patients with good collaterals, only a minority will go on to have a favorable outcome without recanalization \[[@B13]\], suggesting that collaterals are finite and will only persist long enough minimize core growth until spontaneous thrombus autolysis in a small group of patients. It is, however, conceivable that a group of patients with small core infarct and persisting good collateral status may present or may be referred beyond the established therapeutic time window of six hours and may benefit from thrombectomy.

It has been demonstrated that in patients assessed using MR perfusion and treated within 12 hours, those patients with a mismatch between core and penumbra will benefit from reperfusion whereas those that show a matched defect will not \[[@B14]\]. Furthermore, these patients obtained superior outcomes when compared to another population of patients with a target mismatch treated with best medical therapy within the same time frame \[[@B15]\]. Recently, the results of the DAWN trial have been presented \[[@B16]\], suggesting a clear benefit for patients undergoing thrombectomy between 6 and 24 hours compared to best medical therapy when selected using well def ined CT or MR perfusion criteria stipulating small core infarcts with clinico-radiological mismatch. We aimed to assess whether observational evidence obtained in real world practice employing imaging to exclude large core infarcts supported use of EVT after the established six hour therapeutic time window through comparison of results of recent positive trials that selected patients within this time window using conventional imaging with CT and CTA.

MATERIALS AND METHODS
=====================

Literature Search Strategy
--------------------------

Two reviewers systematically searched Ovid Medline, PubMed, Cochrane Central Register of Controlled trials and the Cochrane Database of Systematic Reviews from date of inception to January 2017. To maximize the sensitivity of the search strategy, specific terms were used as either Mesh Categories or key words, including: 'acute stroke', 'endovascular', 'mechanical thrombectomy', 'stent retriever', 'time-to-treatment'. Reference lists and citing articles were also reviewed to increase the identification of relevant studies.

Selection Criteria
------------------

Predefined criteria were selected prior to study review. Those that reported outcomes for acute anterior circulation stroke treated with mechanical thrombectomy in patients selected with MRI or CT techniques beyond 6 hours after symptom onset were included. All publications were published in the English language. Case reports, conference presentations, E-posters, reviews and abstracts were excluded.

The control population was taken from the results of recent randomized trials in which the patients were treated within six hours and selected using CT and CT angiography. This included patients treated in PISTE \[[@B2]\], MR CLEAN \[[@B3]\], and THERAPY \[[@B4]\]. Advanced imaging including collateral scoring on CTA, multiphase CTA, CT perfusion or MR imaging were included within SWIFT PRIME \[[@B17]\], THRACE \[[@B18]\], REVASCAT \[[@B19]\], ESCAPE \[[@B20]\], and EXTEND IA \[[@B21]\] trials and therefore, the results of these trials were not included within the control population.

Baseline demographics including presenting National Institute of Health Stroke Scale (NIHSS) score were extracted along with complicating time to reperfusion, symptomatic hemorrhage, degree of recanalization (Thrombolysis in Myocardial Infarction, TIMI 2 or 3 and Thrombolysis in Cerebral Infarction, TICI 2b/3 were deemed as successful degrees of recanalization respectively), favorable outcomes (modified Rankin Scale, mRS ≤2 at 90 days), and 90 day mortality.

Data Extraction
---------------

Two investigators (JW and AMM) independently reviewed each selected article and tabulated. This was subsequently checked prior to analysis by a third independent reviewer (KP) and papers were included by consensus. Data was extracted from the tables and f igures available from each study. For continuous variables, standard deviations (SD) were collected as much as possible. When SD was not reported, it was estimated using range/4 or interquartile range (IQR)/1.35 \[[@B22][@B23]\]. Each article was appraised according to the Dutch Cochrane Centre checklist proposed by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. The key points included within these criteria include: (i) clear definition of the study population; (ii) clear definition of outcomes and outcome assessment; (iii) independent assessment of outcome parameters; (iv) suff icient duration of follow-up; (v) no selective loss during follow-up; and (vi) important confounders and prognostic factors identified.

Statistical Analysis
--------------------

Following data extraction, comparative statistical analysis was made with the outcomes of three recently published studies assessing outcomes in acute anterior circulation stroke treated with thrombectomy \<6 hours. A meta-analysis of proportions was conducted for the available main perioperative and postoperative variables. Firstly, to establish variance of raw proportions, a logit transformation was applied. To incorporate heterogeneity (anticipated among the included studies), transformed proportions were combined using DerSimonian-Laird random effects models. Finally the pooled estimates were back-transformed. Heterogeneity was evaluated using Cochran Q and I^2^ test. Weighted means were calculated by determining the total number of events divided by total sample size. Subgroup analysis was conducted according to timing of thrombectomy treatment \<6 hours versus \>6 hours. All analyses were performed using the metafor package for R version 3.01. P values \<0.05 were considered statistically significant.

RESULTS
=======

A total of 386 individual studies were identified from the four electronic databases. Following single reviewer evaluation of abstracts, 24 were identified as being eligible for assessment. The full text of these articles was assessed and 8 remaining articles fulf illed inclusion criteria. One study was a prospective single center study, 5 were retrospective single centre studies and 2 were retrospective multicenter studies ([Table 1](#T1){ref-type="table"}).

Baseline Characteristics
------------------------

Baseline characteristics of the eight studies that met criteria for inclusion in this analysis \[[@B24][@B25][@B26][@B27][@B28][@B29][@B30][@B31]\] are summarized in [Table 1](#T1){ref-type="table"}. The total number of patients included was 688. Four studies included patients presenting beyond 8 hours from symptom onset, 3 beyond 6 hours and 1 beyond 7 hours. The mean presenting NIHSS score was 15.7 and the mean time from symptom onset to puncture was 15.1 hours. Patient selection was made using a combination of either CT or MRI techniques in six studies, the two remaining studies utilized CT perfusion only. Recanalization was measured using the TIMI scoring system in 5 of the studies and the TICI system was employed in three studies. The control population contained data from three recent randomized trials \[[@B2][@B3][@B4]\], including 321 patients selected and treated within 6 hours on the basis of CT and CT angiography.

Age and Sex
-----------

No difference in presenting age was found between the two groups (67 vs. 64.7 years for \<6 hours and \>6 hours respectively, P=0.24). The proportion of females was also similarly matched (43.8% vs. 43.6%, P=0.92).

Imaging selection criteria
--------------------------

Imaging used to select patients in each study is described in [Table 2](#T2){ref-type="table"}.

Time to puncture and presenting NIHSS
-------------------------------------

The pooled mean of time to puncture, defined as time from symptom onset to groin puncture was 4.0 vs. 15.1 hours, P=0.001). The presenting NIHSS score was greater for the \<6 hour group (17.1 vs. 15.7, P=0.02).

Procedural Parameters
---------------------

Weighted pooled estimates of successful recanalization (defined as TICI 2b/3 or TIMI 2/3) were (70.6% (95% CI: 53.3-83.5) vs. 70.1% (95% CI: 63.4-76.0), P=0.75) for patients treated \<6 hours and \>6 hours respectively ([Fig. 1](#F1){ref-type="fig"}). Symptomatic intracranial hemorrhage was similar between the two populations: (7.7% (95% CI: 5.1-11.4) vs. 10.0 (95% CI: 6.7-14.7, P=0.33); see [Figure 2](#F2){ref-type="fig"}.

Functional outcomes and mortality
---------------------------------

Favorable outcome (defined as mRS ≤2) was found to be similar (38.4% (95% CI: 28.9-48.9) vs. 38.9 (95% CI; 31.9-46.4), P=0.88); see [Figure 3](#F3){ref-type="fig"}. Mortality was significantly higher for those selected using perfusion and treated beyond 6 hours (12.5% (95% CI: 7.3-20.4) vs. 22.8% (95% CI: 19.8-26.1, p\<0.0001); see [Figure 4](#F4){ref-type="fig"}.

DISCUSSION
==========

Analysis of the recent randomized control trials assessing outcomes for proximal large vessel occlusive ischemic stroke treated with EVT has demonstrated a clear benefit over intra-venous thrombolysis alone/best medical therapy within a 7.3 hour therapeutic window from symptom onset \[[@B1]\]. Three trials relied on use of CT and CTA for patient selection and treatment within 6 hours. The other trials used various advanced imaging techniques including multiphase CTA, collateral scoring, CT or MR perfusion or diffusion imaging. Nevertheless, it is well established that favorable outcome rate falls with time from symptom onset, but, is has been established that core infarct size is independent of time to presentation \[[@B4]\] and it is well documented that collateral flow is critical in stroke physiology \[[@B32]\]. A robust collateral network may be associated with smaller initial infarct volumes, reduced rates of infarct growth, improved outcomes, reduced rates of procedural related intra-cranial hemorrhage and increased rates of successful recanalization \[[@B33][@B34]\] Good collaterals alone do not guarantee a favorable outcome \[[@B7]\] and recanalization is key to achieving this. The DEFUSE 2 study demonstrated that those patients with a target mismatch treated with EVT showed benefit from reperfusion whereas those that show a matched defect did not \[[@B14]\]. More recently, it has been shown that these patients obtained superior outcomes when compared to another population of patients with a target mismatch treated with best medical therapy \[[@B15]\] It is possible, therefore, that even for those patients presenting beyond the established therapeutic time window, there is a subset with favorable collateral status and small core infarct (hence a target mismatch) that may also benefit from thrombectomy.

The results of the eagerly awaited DAWN trial \[[@B16]\] were presented recently, reporting a 35% absolute increase in the number of patients achieving independence with number needed to treat of 2.8 after undergoing thrombectomy selected using advanced imaging after 6 hours. Selection criteria for those under 80 years included an NIHSS \>10 with core infarct volume of \<31 ml or NIHSS score of \>20 with core \<51 ml and for those over 80 years, an NIHSS of \>10 and core of \<21 ml. In this analysis, all patients other than f ive were selected on the basis of a core infarct \<one third of the MCA territory, or on the basis of the absence of T2 hyperintensity on MRI or low CT or MR ASPECTS (Alberta Stroke Program Early CT Score) score. Furthermore, all patients other than 74 from two of the studies included \[[@B27][@B30]\] were defined as having a mismatch on perfusion imaging. Perfusion imaging was recommended in one of these studies that provided 52 patients \[[@B30]\] but a mismatch was not def ined as a criterion for inclusion and we have no data on the proportion with a mismatch in this study. The imaging criteria in this analysis are therefore heterogenous and less selective than those used in the DAWN trial. However, they more likely reflect clinical practice.

We aimed to assess whether available observational evidence obtained in real world practice supported the approach of treating patients beyond 6 hours on the basis of favorable imaging with limited core infarct. We also aimed to assess whether comparable results to those achieved using conventional imaging selection (CT/CTA) for patients treated within 6 hours could be obtained. It is somewhat artificial to compare these groups but the latter group of patients selected using CT/CTA within 6 hours represent selection criteria included in many national/international guidelines and the data are taken from prospective trials selecting on this basis. The study population included in this meta-analysis comprised patient selection using either CT or MRI to identify a limited core infarct with the majority undergoing perfusion techniques to identify a mismatch beyond the standard 6 hour therapeutic window. With a mean time of presentation to puncture of 15.1 hours, the patients showed good functional outcome (mRS ≤2) in 38.9%. This was not significantly different to rates of independence encountered in the control population treated within 6 hours selected using conventional imaging (mRS ≤2 in 38.4%), P=0.88. The delayed recanalisation group did show a significant increase in mortality compared to those treated within the conventional time window (12.5% vs. 22.8%, P\<0.0001). However, the rate of symptomatic intra-cranial hemorrhage did not differ signif icantly (7.7% vs. 10.0%, P=0.33).

It is likely that selecting patients on the basis of CT and CTA will lead to treatment of a proportion of patients with a matched core and penumbra despite undergoing a procedure within 6 hours. The superior outcomes obtained in the EXTEND-IA trial \[[@B21]\] that selected on the basis of a target mismatch identified with CT perfusion within 6 hours does go some way to proving this. The favorable outcome rate (mRS≤2) in this trial was 66%. Furthermore, Turk et al. \[[@B27]\] demonstrated that there was no significant difference in functional outcome for those selected on the basis of a target mismatch on CT perfusion treated before or after 7 hours, with the median treatment time in the latter group being 13 hours.

It is not clear from available results why there was increased mortality in the delayed treatment group. This modest increase in symptomatic intracranial hemorrhage, did not reach statistical significance, and on the face of it is unlikely to have contributed to the increase in mortality. The use of older endovascular technology in a significant proportion is a confounder and could have been a factor \[[@B35]\]. However, recanalization rates and hemorrhage were not dissimilar so this impact is uncertain. The 'no reflow phenomenon' would hopefully be avoided through the use of perfusion imaging and selection of patients with a mismatch. One possible explanation and a question raised by the results is whether reperfusion injury is more common in this group. Reperfusion injury is characterized by a complex interaction between activated inflammatory mediators and the endothelial layer of the capillary wall resulting in capillary plugging, breakdown of the blood brain barrier and inf iltration of localized brain parenchyma with cytokines \[[@B36]\]. This inflammatory cascade leads to an increased tendency towards hemorrhagic transformation and increased cerebral edema respectively \[[@B36]\]. However, these studies excluded patients with a large core infarct so again, the impact of reperfusion injury is uncertain. What is necessary is to ascertain the mortality from the natural history for this population of late presenters with a limited core infarct.

Successful recanalization was achieved in 70.1% of the study population selected using perfusion imaging \>6 hours, comparing well with the trial data (TICI 2b/3 in 70.6%) despite use of older technology in a significant proportion. Thrombus characteristics are a potential factor in determining recanalization rate. It is well established that the attenuation characteristics of acute thrombus reduce with time as red cell rich clots evolve to more fibrin rich variants \[[@B37]\]. Authors who have found lower rates of recanalization with more fibrin rich clots therefore suggest that thrombi become more difficult to remove with time \[[@B37]\]. Thrombus length, or 'clot burden' is inversely related to outcome and successful recanalization with an increasing clot burden score being associated with worse functional outcomes and larger final infarcts volume \[[@B37][@B38][@B39]\]. Clot burden is however independent of time and is instead related to collateral status \[[@B40]\]. Potential explanations for this relationship include improved access of the distal clot to thrombolytics from retrograde filling and reduced stasis preventing clot propagation \[[@B41]\]. We therefore suggest that although the constituents of clot change with time, these target lesions will not necessarily be of long length, a relationship that may balance difficulty of clot extraction in this patient cohort.

This analysis is limited through inclusion of a number of single centre retrospective studies but this reflects the best estimate that we have currently of real-world practice with less stringent selection criteria that may be encountered in the trial scenario. The studies varied in inclusion criteria: most looked specif ically at anterior circulation stroke however two included a small percentage of posterior circulation strokes and wake-up strokes respectively \[[@B24][@B25][@B26][@B27]\]. Jung et al. \[[@B27]\] included patients with a baseline NIHSS score ≥4, or isolated hemianopia whereas Turk et al. \[[@B29]\] included patients with an NIHSS \>8 with any symptomatology. The imaging modalities and protocols varied between studies. For example, Abou-Chebal \[[@B24]\] included patients only selected with CT perfusion whereas Jovin et al. \[[@B25]\] utilized NCCT and MR perfusion with different studies employing different exclusion criteria based on imaging. Although there is inherent variability in the information provided between imaging modalities and also between different manufacturers and systems within each modality, for practical use to decision-make in this setting good agreement has been found \[[@B42]\]. Finally, recanalization was measured using different grading systems in the study cohort with both TICI and TIMI scoring utilized. A study comparing the different scales has however shown comparable outcomes for patients with TICI 2b/3 and TIMI 2/3 recanalization \[[@B43]\] and therefore the impact of this on results is likely minimal. These limitations should be considered when interpreting the results of this review.

CONCLUSION
==========

Recent studies have shown a clear benefit of EVT over IV-TPA alone in acute large vessel occlusive ischemic stroke within 6 hours of symptom onset. Our pragmatic meta-analysis of observational studies suggests that the rates of recanalization and good functional outcome are not significantly different to this in patients treated beyond 6 hours when selected on the basis of desirable imaging characteristics demonstrating limited core infarction (the majority def ined as core of less than one third the MCA territory). We also demonstrated an increase in mortality but no difference in the rate of symptomatic intracranial hemorrhage. The reasons for this increase in mortality remain unclear based on available data. Although the results of prospective studies investigating this clinical scenario are eagerly awaited, these results suggest that patients who present in a delayed manner with a limited core infarct may benefit from recanalization with thrombectomy.
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###### Baseline Characteristics and Peri-Operative Outcomes for Those Treated \>6 Hours Selected Using Advanced Imaging and for Those Treated \<6 Hours Selected Using CT/CTA
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Patients treated \>6 hrs selected using advanced imaging   Patients treated \<6 hrs selected using CT/CTA                                                                                                                                          
  ------------------------------------------------ ---------------------------------------------------------- ------------------------------------------------ --------------- --------------------- ----------------- ------------ --------------- --------------- ------------ -------------------- ------------------
  Patients                                         21                                                         237                                              128             22                    30                70           52              128             33           233                  55

  Age, years (M=mean/SD.m=median/IQR)              M 59.4 (17.2)                                              M 63.8 (16)                                      M 61.1 (15)     M 67.1 (14.5)         m 72 (24-91)      M 64.9       M 66.3 (12.4)   M 64            M 67 (17)    m 65.8 (54.5-76.0)   M 67 (11)

  Females N/%                                      8 (38%)                                                    121 (51)                                         59 (46.1)       10 (45.5)             13 (43)           31 (45%)     21 (40.4)       43 (41)         20 (61%)     98 (42%)             38 (21)

  Onset To Puncture hrs (M=mean/SD.m=median/IQR)   M 18.6 (16.0)                                              M 15.0 (11.2)                                    m 6.8 (6-24)\   m 10.35 (8.2-23.7)\   m10.0 (8-27.5)\   M18.3        M8.38 (3.25)    M 18.2 (33.6)   m 3.5        m 4.33 (3.5-5.2)     m 3.8 (3.06-4.4)
                                                                                                                                                               M15 (13.3)      M15.9 (11.5)          M17.75 (14.4)                                                                                    

  Presenting NIHSS (M=mean/SD.m=median/IQR)        M 17.8 (5.5)                                               M 15.0 (5.5)                                     M 16.1 (9.1)    m 16.5 (8-22)\        m 12 (5-22)\      M 15.1       M 17.3 (4.8)    M 14.5 (5.4)    m18 (6-24)   m 17 (14-21)         m 17 (13-22)
                                                                                                                                                                               M15 (10.3)            M13.5 (12.6)                                                                                     

  TICI 2b/3/TIMI 2/3 N/%                           18 (85.7)                                                  175 (73.84)                                      81 (64.8)       15 (68.2)             20/30 (66.7)      58 (82.60)   28 (53.8)       90 (70)         26/30 (87)   115/196 (58.7)       30/43 (70)

  ICH Symptomatic N/%                              2 (9.5)                                                    21 (8.86)                                        23 (3.7)        2 (9.0)               3/30 (10)         4/70 (5.6)   3/52 (5.8)      NA              0            18 (7.7)             4/43 (9.3)

  mRS ≤2 at 3 months N/%                           9 (42.9)                                                   93/198 (47.0)                                    43/122 (35.2)   8 (36.4)              6 (20)            32 (45.5)    12 (23.1)       64 (50)         17 (51.5)    76 (32.6)            19/50 (38)

  90 Day Mortality N/%                             5 (23.8)                                                   51 (21.5)                                        32/122 (26.2)   4 (18.2)              9 (33)            15 (21.2)    11 (21.2)       28 (22)         7 (21.2)     21/233 (9)           6/50 (12)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Imaging Criteria Applied in Each Study
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  Study                     Selection criteria
  ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abou-Chebal[@B24]         CT perfusion mismatch defined by the presence of a low CBF region that measured ≥20% of the low CBV region. Exclusion if core infarct based on CBV map \> one third of the MCA territory.
  Jovin et al[@B25]         Visual inspection of MRI or CTP scans demonstrating mismatch between core (DWI or CTP-CBV lesion) and inadequately perfused brain (CBF, MTT, or TTP MRI or CTP maps). Exclusion if core infarct greater than one third of the MCA territory.
  Jung et al[@B26]          NCCT assessed for core infarct and MR perfusion and diffusion weighted MR imaging mismatch assessed by visual inspection. EVT not performed if no relevant diffusion-perfusion mismatch on MRI, if the spin-echo T2- weighted images revealed clearly visible hyperintense T2 signal, or if the CT showed extensive hypodensity.
  Gratz et al[@B27]         Perfusion criteria not defined. The majority of patients underwent MRI (median ASPECTS 6.5). 77% showed moderate-good leptomeningeal collateral flow on DSA. Patients undergoing CT only had a median ASPECTS of 8.5. No exclusion criteria but 5 (22%) had extensive ischaemic changes defined as ASPECTS \<5.
  Natarajan et al[@B28]     Patients with "significant salvageable brain tissue" were selected on the basis of preserved CBV maps. Patients considered for treatment if established core infarct was less than one-third of the MCA territory or ASPECTS ≥7.
  Turk et al[@B29]          MTT/CBF defined penumbra and CBV defined core mismatch. Patients in whom one-third or more of the MCA territory was core infarct or with ≤50% penumbra were not considered candidates for endovascular treatment.
  Abilleira et al[@B30]     Perfusion imaging not defined. CT ASPECTS \<7 and DWI ASPECTS \<6 or patients with well-developed parenchymal hyperintensity seen on FLAIR or pronounced hypodensity on CT affecting the ischemic region excluded.
  Aghaebrahim et al[@B31]   Patients included if CT showed an ASPECTS score \>6 or less than one-third hypodensity within the MCA territory. CT perfusion CBV/MTT mismatch or CBV/NIHSS mismatch considered. Patients with a core volume less than a third of the vascular territory involved in the presence of an anterior circulation large vessel occlusion and corresponding clinical deficit (NIHSS \>6-8) or severe perfusion deficit (MTT \>145% contralateral side) involving two-thirds or more of the vascular territory involved were considered for EVT.

ASPECTS: Alberta Stroke Program Early CT Score; CBF: Cerebral Blood Flow; CBV: Cerebral Blood Volume; CTP: CT Perfusion; DSA: Digital Subtraction Angiography; DWI: Diffusion Weighted Imaging; MCA: Middle Cerebral Artery; MTT: Mean Transit Time; NCCT: Noncontrast CT; NIHSS: National Institute of Health Stroke Scale; TTP: Time to Peak
